Pancrelipase controlled-release - Digestive Care

Drug Profile

Pancrelipase controlled-release - Digestive Care

Alternative Names: PANCRECARB® MS-16; Pancrelipase delayed release capsules - Digestive Care; Pertzye; Pertzyme

Latest Information Update: 19 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Digestive Care
  • Developer Chiesi USA; Digestive Care
  • Class Pancreatic enzymes
  • Mechanism of Action Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Exocrine pancreatic insufficiency

Most Recent Events

  • 14 Jul 2017 Registered for Exocrine pancreatic insufficiency (In adolescents, In adults, In children, In infants) in USA (PO)
  • 01 Dec 2016 Mayo Clinic and Digestive Care initiate enrolment in a phase I/II trial for Exocrine pancreatic insufficiency (unresectable pancreatic cancer associated) in USA (NCT02985801)
  • 12 Oct 2016 Launched for Exocrine pancreatic insufficiency (In infants) in USA in October 2016 (PO, 4000 USP lipase units/capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top